JP2016510594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510594A5 JP2016510594A5 JP2015561628A JP2015561628A JP2016510594A5 JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5 JP 2015561628 A JP2015561628 A JP 2015561628A JP 2015561628 A JP2015561628 A JP 2015561628A JP 2016510594 A5 JP2016510594 A5 JP 2016510594A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- heparanase
- cells
- specific
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772591P | 2013-03-05 | 2013-03-05 | |
| US61/772,591 | 2013-03-05 | ||
| PCT/US2014/020936 WO2014138315A1 (en) | 2013-03-05 | 2014-03-05 | Heparanase expression in human t lymphocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510594A JP2016510594A (ja) | 2016-04-11 |
| JP2016510594A5 true JP2016510594A5 (https=) | 2017-04-06 |
Family
ID=50397277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561628A Ceased JP2016510594A (ja) | 2013-03-05 | 2014-03-05 | Ｔリンパ球におけるヘパラナーゼの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160017302A1 (https=) |
| EP (1) | EP2964253A1 (https=) |
| JP (1) | JP2016510594A (https=) |
| CN (1) | CN105407914A (https=) |
| AU (1) | AU2014225708B2 (https=) |
| CA (1) | CA2904236A1 (https=) |
| HK (1) | HK1220111A1 (https=) |
| WO (1) | WO2014138315A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| JP7086375B2 (ja) | 2015-04-23 | 2022-06-20 | ベイラー カレッジ オブ メディスン | 生体内での存続性及び治療活性及びその増殖のためのｎｋｔ細胞サブセット |
| WO2016187459A1 (en) | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| JP6949728B2 (ja) * | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
| MX2018005274A (es) | 2015-10-30 | 2019-09-19 | The Regents Of The Universtiy Of California | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. |
| WO2017117521A1 (en) * | 2015-12-31 | 2017-07-06 | Berkeley Lights, Inc. | Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| CA3048645A1 (en) | 2016-12-30 | 2018-07-05 | The Regents Of The University Of California | Methods for selection and generation of genome edited t cells |
| EP3600447A4 (en) * | 2017-03-20 | 2020-12-30 | Baylor College of Medicine | TRANSGENIC C-MPL TO INTRODUCE LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS INTO GENETICALLY MODIFIED CELLS BY TCR |
| WO2020123938A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| US12291560B2 (en) | 2018-12-14 | 2025-05-06 | Regeneron Pharmaceuticals, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| US12421315B2 (en) | 2019-05-08 | 2025-09-23 | Regeneron Pharmaceuticals, Inc. | CLL-1 targeted immunotherapies |
| CN114450397A (zh) * | 2019-08-01 | 2022-05-06 | 纪念斯隆-凯特琳癌症中心 | 用于改善免疫疗法的细胞及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5968822A (en) * | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| CA2432157A1 (en) * | 2000-12-19 | 2002-06-27 | Insight Strategy And Marketing Ltd. | The use of ecm degrading enzymes for the improvement of cell transplantation |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2007034480A2 (en) * | 2005-09-20 | 2007-03-29 | Carmel-Haifa University Economic Corp. Ltd | Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP3467101A3 (en) * | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
-
2014
- 2014-03-05 EP EP14714474.5A patent/EP2964253A1/en not_active Withdrawn
- 2014-03-05 CA CA2904236A patent/CA2904236A1/en not_active Abandoned
- 2014-03-05 JP JP2015561628A patent/JP2016510594A/ja not_active Ceased
- 2014-03-05 CN CN201480025440.0A patent/CN105407914A/zh active Pending
- 2014-03-05 US US14/773,330 patent/US20160017302A1/en not_active Abandoned
- 2014-03-05 AU AU2014225708A patent/AU2014225708B2/en not_active Expired - Fee Related
- 2014-03-05 WO PCT/US2014/020936 patent/WO2014138315A1/en not_active Ceased
- 2014-03-05 HK HK16108046.9A patent/HK1220111A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510594A5 (https=) | ||
| MX2023001878A (es) | Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t. | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| MX2023012264A (es) | Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico. | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
| WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| MY185961A (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| MY205684A (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| EP4219725A3 (en) | Altering gene expression in modified t cells and uses thereof | |
| MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
| MY187624A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor | |
| WO2013040557A3 (en) | Rna engineered t cells for the treatment of cancer | |
| EP4279086A3 (en) | Compositions and methods for treating cancer with anti-cd19 immunotherapy | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| MX2017004691A (es) | Bloqueo de cd73. | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| MX2017011600A (es) | Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. |